Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure | Zendy

Estefanía Oliveros | Zendy; Ebenezer Oni | Zendy; Anum Shahzad | Zendy; Aaron Y. Kluger | Zendy; Kevin Bryan Lo | Zendy; Janani Rangaswami | Zendy; Peter A. McCullough | Zendy

Open Access

Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure

Author(s) -

Estefanía Oliveros,

Ebenezer Oni,

Anum Shahzad,

Aaron Y. Kluger,

Kevin Bryan Lo,

Janani Rangaswami,

Peter A. McCullough

Publication year - 2020

Publication title -

cardiorenal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.661

H-Index - 21

eISSN - 1664-3828

pISSN - 1664-5502

DOI - 10.1159/000504167

Subject(s) - medicine , heart failure , aldosterone , renin–angiotensin system , angiotensin ii , mineralocorticoid receptor , spironolactone , endocrinology , intensive care medicine , cardiology , pharmacology , receptor , blood pressure

The renin-angiotensin-aldosterone axis plays a pivotal role in the pathophysiology of acute and chronic heart failure (HF) and represents an important target for guideline-directed medical therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research